Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: A large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation

International Journal of Hematology

Volumn 79, Issue 5, 2004, Pages 495-500

  Ogawa, Hiroyasu ^a   Ikegame, Kazuhiro ^a   Kawakami, Manabu ^a   Takahashi, Satoshi ^b   Sakamaki, Hisashi ^c   Karasuno, Takahiro ^d   Sao, Hiroshi ^e   Kodera, Yoshihisa ^f   Hirabayashi, Noriyuki ^g   Okamoto, Shinichiro ^h   Harada, Mine ⁱ   Iwato, Koji ^j   Maruta, Atsuo ^k   Tanimoto, Mitsune ^l   Kawa, Keisei ^m  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e Meitetsu Hospital   (Japan)

^f JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^g NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^k KANAGAWA CANCER CENTER   (Japan)

^l OKAYAMA UNIVERSITY   (Japan)

^m RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

more..

Author keywords

Acute myeloid leukemia; Allogeneic related stem cell transplantation; Allogeneic unrelated stem cell transplantation; Autologous stem cell transplantation; Cytogenetics

Indexed keywords

CYCLOSPORIN; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CYTOGENETICS; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHROMOSOME ABERRATIONS; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 3042662208     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.03166     Document Type: Article

References (22)

1. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML Trial (MRC AML 10). Blood. 1997;89:2311-2318.
2. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
3. Zittoun R, Jehn U, Fiere C, et al. Alternating repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood. 1989;73:896-906.
4. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988;6:583-587.
5. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700-708.
6. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924-1930.
7. Linker CA, Ries CA, Damon LE, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000;6:50-57.
8. Cassileth PA, Anderson J, Lazarus HN, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993;11:314-319.
9. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-223.
10. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission - a European Group for Blood and Marrow Transplantation study. Blood. 1997;90:2931-2938.
11. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood. 2003;102:1232-1240.
12. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
13. Mrózek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 2000;72:261-271.
14. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
15. Keating S, Suciu S, de Witte T, et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1996;17:993-1001.
16. Chalandon Y, Barnett MJ, Horsman DE, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2002;8:435-443.
17. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995;16:203-208.
18. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
19. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
20. Knechtli CJC, Goulden NJ, Hancock JE, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood. 1998;92:4072-4079.
21. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9:206-212.
22. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101:1698-1704.